title: [Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin)as salvage chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML).
  
  
  METHODS
  We retrospectively analyzed 64 patients with refractory/relapsed AML who received the HAA regimen as salvage chemotherapy. The complete remission (CR)rate was analyzed. Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS), and the differences were compared by Log-rank test.
  
  
  RESULTS
  The overall CR rate was 70.1%, and 67.1% of the patients attained CR after the first induction course. The early death rate was 0. The median follow-up time was 61 (range:6-120) months. The estimated 3-year OS rate was 46.8% and the estimated 3-year RFS rate was 42.8%. The CR rates of patients with favorable/intermediate and unfavorable cytogenetics were 76.4% and 33.3%, respectively. The 3-year OS of favorable/intermediate and unfavorable group were 53.7% and 10.0%, respectively. The median survival time of unfavorable group was only 8 months. The side effects associated with the HAA regimen were tolerable, in which the most common toxicities were myelosuppression and infection.
  
  
  CONCLUSIONS
  HAA regimen is associated with a higher rate of CR and longer-term survival and its toxicity can be tolerated. The regimen is suitable for refractory/relapsed AML patients with favorable or intermediate risk .
authors.affiliation: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
authors.forename: Cuihua
authors.initials: C
authors.lastname: Fan
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Yu
authors.forename: Wenyuan
authors.initials: W
authors.lastname: Mai
authors.forename: Haitao
authors.initials: H
authors.lastname: Meng
authors.forename: Wenbin
authors.initials: W
authors.lastname: Qian
authors.forename: Hongyan
authors.initials: H
authors.lastname: Tong
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Liping
authors.initials: L
authors.lastname: Mao
authors.forename: Shanshan
authors.initials: S
authors.lastname: Suo
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D015250:Aclarubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine / Q000627:therapeutic use; D006248:Harringtonines / Q000627:therapeutic use; D000077863:Homoharringtonine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate
chemical_list: D006248:Harringtonines; C011157:aclacinomycins; D003561:Cytarabine; D000077863:Homoharringtonine; D015250:Aclarubicin